JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?

JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
复制标题

DOI:
10.1007/s11926-018-0792-7
复制
发表时间:
2018-11-08
影响因子:
5
通讯作者:
McInnes IB
McInnes IB
中科院分区:
医学2区
文献类型:
--
作者:
Kerrigan SA;McInnes IB

文献摘要

参考文献

被引文献

相似文献

鉴于最近Janus激酶抑制剂(JAKinibs)在成人风湿性疾病患者中的使用和使用增加,我们旨在审查目前在儿科风湿病患者中使用的证据。在过去的二十年里,风湿性疾病的治疗取得了重大进展。在成人和儿童中引入生物制剂显著改善了患者结局,并提高了生活质量。此外,对类似药物的反应暗示了特别是在青少年和成人滑膜炎中起作用的共同效应途径。然而,这些药物的无效性和不耐受性导致一部分儿童的治疗选择有限。自2012年以来,Janus激酶(JAK)抑制剂(JAKinibs),一种新型的口服小分子抑制剂,已证明其在几种形式的成人炎性关节炎中的疗效,如类风湿性关节炎(RA)和银屑病关节炎(PsA)。希望这些成功将转移到儿科人群。在下面的综述中,我们将讨论JAKinibs在这方面的发展和进展。
Given the recent increase in the profile and use of Janus kinase inhibitors (JAKinibs) in adult patients with rheumatic diseases, we aimed to review the current evidence accruing for use in paediatric rheumatology patients. Significant advances have been made in the management of rheumatic diseases in the past two decades. The introduction of biologic agents in both adults and children has provided significant improvements to patient outcomes and led to better quality of life. Moreover, responses to similar agents allude to common effector pathways operating across juvenile and adult synovitis especially. However, inefficacy and intolerance of these agents leads to a subset of children with limited treatment options. Since 2012, Janus kinase (JAK) inhibitors (JAKinibs), a novel group of oral small molecule inhibitors, have demonstrated their efficacy in several forms of adult inflammatory arthritis, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). There are hopes that these successes will be transferable to the paediatric population. In the following review, we discuss the development and progress of JAKinibs in this regard.
DOI: 10.1136/annrheumdis-2016-210457
发表时间: 2017-07
影响因子: 27.4
作者:
Cohen SB;Tanaka Y;Mariette X;Curtis JR;Lee EB;Nash P;Winthrop KL;Charles-Schoeman C;Thirunavukkarasu K;DeMasi R;Geier J;Kwok K;Wang L;Riese R;Wollenhaupt J
通讯作者: Wollenhaupt J
DOI: 10.1016/j.jaut.2014.01.009
发表时间: 2014-02-01
影响因子: 12.8
作者:
Eisenstein, Eli M.;Berkun, Yackov
通讯作者: Berkun, Yackov
DOI: 10.1021/jm401490p
发表时间: 2014-06-26
影响因子: 7.3
作者:
Clark, James D.;Flanagan, Mark E.;Telliez, Jean-Baptiste
通讯作者: Telliez, Jean-Baptiste
DOI: 10.1002/art.40122
发表时间: 2017-07-01
影响因子: 13.3
作者:
Fremond, Marie-Louise;Uggenti, Carolina;Rodero, Mathieu P.
通讯作者: Rodero, Mathieu P.
DOI: 10.1007/s40265-017-0701-9
发表时间: 2017-04
期刊: Drugs
影响因子: 11.5
作者:
Banerjee S;Biehl A;Gadina M;Hasni S;Schwartz DM
通讯作者: Schwartz DM